Does BPC-157 heal torn tendons in humans?

There is no published human trial of BPC-157 for tendon repair. Every specific 'BPC-157 heals tendons' claim online is extrapolation from rat Achilles and quadriceps tendon models. The rat literature is substantial and mechanistically coherent; the human evidence base for tendon specifically is empty. Treat 'BPC-157 healed my rotator cuff' anecdotes as anecdote, not as evidence that generalizes.

Why is the preclinical evidence so heavily concentrated in one research program?

Because a single research program at the University of Zagreb, led since the mid-1990s by Predrag Sikiric, has authored the majority of BPC-157 papers, including most of the tendon work. This is both a strength (deep methodological consistency) and a weakness (limited independent replication from unrelated labs). Gwyer et al. 2019 is one of the few reviews from outside the Zagreb group and is worth reading specifically for that reason.

What outcome measures do the rat tendon studies use?

A mix of macroscopic healing grades, histologic scoring of collagen organization, and biomechanical tensile-strength testing. The biomechanical endpoints are the most interpretable, 'force to failure' is a clean number. What these endpoints do not measure is the thing patients care about: return to sport, persistent function, re-rupture rate. Rat endpoints and patient endpoints are different questions.

Is there any route-of-administration data that matters?

Most rat studies used intraperitoneal or intragastric administration. The oral dose used in Chang et al. 2014 (the non-tendon human pilot) was 50 mcg/kg. Injectable subcutaneous administration, the most common route in the research-chemical channel, has not been directly compared head-to-head with oral or intraperitoneal at human scale in a tendon endpoint. The route assumption in online discussion frequently outruns the route evidence.

What would actually change PepVise's assessment?

A published, adequately-powered, placebo-controlled randomized trial of BPC-157 in a defined tendon indication (Achilles, rotator cuff, patellar) with clinically meaningful outcomes (return to activity, re-rupture, patient-reported function) at 6-12 months. That trial does not exist. When it does, we will update. Until then, the tendon-repair claim sits at 'strong preclinical signal, no human validation', the evidence ledger has not moved in five years.

Explainer· Evidence

BPC-157 for tendon repair

By The PepVise Editorial Team · Reviewed April 21, 2026 · 12 min read

Inclusion criteria, 8-10 preclinical studies tabulated, the human evidence gap, and an honest assessment of the tendon claims.

Mechanism explainers on PepVise aim for textbook-level clarity without the textbook's refusal to commit to a reading.

Frequently asked

What readers ask us next.

Does BPC-157 heal torn tendons in humans?: There is no published human trial of BPC-157 for tendon repair. Every specific 'BPC-157 heals tendons' claim online is extrapolation from rat Achilles and quadriceps tendon models. The rat literature is substantial and mechanistically coherent; the human evidence base for tendon specifically is empty. Treat 'BPC-157 healed my rotator cuff' anecdotes as anecdote, not as evidence that generalizes.
Why is the preclinical evidence so heavily concentrated in one research program?: Because a single research program at the University of Zagreb, led since the mid-1990s by Predrag Sikiric, has authored the majority of BPC-157 papers, including most of the tendon work. This is both a strength (deep methodological consistency) and a weakness (limited independent replication from unrelated labs). Gwyer et al. 2019 is one of the few reviews from outside the Zagreb group and is worth reading specifically for that reason.
What outcome measures do the rat tendon studies use?: A mix of macroscopic healing grades, histologic scoring of collagen organization, and biomechanical tensile-strength testing. The biomechanical endpoints are the most interpretable, 'force to failure' is a clean number. What these endpoints do not measure is the thing patients care about: return to sport, persistent function, re-rupture rate. Rat endpoints and patient endpoints are different questions.
Is there any route-of-administration data that matters?: Most rat studies used intraperitoneal or intragastric administration. The oral dose used in Chang et al. 2014 (the non-tendon human pilot) was 50 mcg/kg. Injectable subcutaneous administration, the most common route in the research-chemical channel, has not been directly compared head-to-head with oral or intraperitoneal at human scale in a tendon endpoint. The route assumption in online discussion frequently outruns the route evidence.
What would actually change PepVise's assessment?: A published, adequately-powered, placebo-controlled randomized trial of BPC-157 in a defined tendon indication (Achilles, rotator cuff, patellar) with clinically meaningful outcomes (return to activity, re-rupture, patient-reported function) at 6-12 months. That trial does not exist. When it does, we will update. Until then, the tendon-repair claim sits at 'strong preclinical signal, no human validation', the evidence ledger has not moved in five years.

The sources

References cited on this page.

PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Adjacent in the literature.

Evidence · Compound profile

Peptides for Weight Loss: What Actually Works

One peptide class genuinely drives weight loss in trials. The rest, sold as fat-loss peptides in the research-chemical channel, range from weakly supported to abandoned. An honest map of both.

12 min read

Evidence · Compound profile

Peptides for Muscle Growth: The Evidence, Graded

Growth-hormone secretagogues, IGF-1 peptides and collagen all get sold for muscle. What the human trials actually show, why GH peptides disappoint lifters, and the legal options that beat all of them.

11 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.